Ordinary Adjustment | DER AKTIONÄR North America Cannabis Select 10 Performance-Index | Effective Date 20th February 2026

Why It Matters

Including high‑growth cannabis and pharma players enhances the index’s relevance for investors seeking exposure to evolving regulatory and therapeutic trends in North America.

Key Takeaways

• Four new constituents added to the cannabis performance index
• Includes both pure‑cannabis and pharma companies
• Adjustment effective 20 Feb 2026
• Reflects broader North American therapeutic market exposure

Pulse Analysis

The recent ordinary adjustment to the DER AKTIONÄR North America Cannabis Select 10 Performance‑Index underscores the growing convergence between cannabis and pharmaceutical sectors. By incorporating Jazz Pharmaceuticals, a leader in specialty medicines, and Tilray Brands, a prominent cannabis producer, the index captures the expanding pipeline of cannabinoid‑based therapeutics. This blend signals investors that the index is not merely tracking recreational cannabis stocks but is also positioning itself to benefit from clinical research, FDA approvals, and cross‑industry collaborations.

Regulatory dynamics in the United States and Canada continue to shape market fundamentals. Recent legislative moves have eased restrictions on medical cannabis, while the FDA’s increasing openness to cannabinoid trials fuels optimism for pharma‑cannabis synergies. Adding Innovative Industrial Proper and Scotts Miracle‑A further diversifies the index, bringing in companies with ancillary roles in industrial applications and consumer products that may leverage cannabis derivatives. This broader composition helps mitigate concentration risk and aligns the index with the evolving definition of “cannabis‑related” equities.

For portfolio managers, the adjustment offers a more nuanced exposure to a sector poised for double‑digit growth. The inclusion of established pharma players provides a stability anchor, while pure‑play cannabis firms contribute higher volatility and upside potential. As institutional capital flows into regulated cannabis markets, indices like DER AKTIONÄR’s serve as benchmarks for performance‑based strategies, enabling investors to track sector momentum without the need to select individual stocks. The updated lineup therefore enhances both the index’s representativeness and its appeal to a wider investor base.